SCHEMBL9944253

SCHEMBL9944253

CC(=O)c1ccc(NC(=O)c2cc(OC(C)C)c(F)c(OC(C)C)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.50
ALDH1A1 P00352 5/20 0.50
MAPK1 P28482 2/20 0.50
TOP1 P11387 1/20 0.50
KCNQ3 O43525 1/20 0.49
KCNQ2 O43526 1/20 0.49
RAB9A P51151 7/20 0.48
NPC1 O15118 6/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
POLB P06746 2/20 0.48
KMT2A Q03164 2/20 0.48
TDP1 Q9NUW8 1/20 0.46
TP53 P04637 4/20 0.46
LMNA P02545 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MCL1 Q07820 1/20 0.46
HSD17B10 Q99714 1/20 0.46
RORC P51449 1/20 0.45
ATM Q13315 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1458273 0.89 MITF (0.55) MAPTALDH1A1MAPK1TOP1KCNQ3
SCHEMBL1458679 0.88 NPC1 (0.61) MAPTALDH1A1MAPK1KCNQ3KCNQ2
SCHEMBL9944248 0.86 RORC (0.51) MAPTALDH1A1MAPK1TOP1KCNQ3
SCHEMBL9944247 0.86 RAB9A (0.55) MAPTALDH1A1MAPK1TOP1RAB9A
SCHEMBL9944326 0.84 MAPT (0.46) MAPTALDH1A1MAPK1TOP1KCNQ3
SCHEMBL9944254 0.83 SMN1; SMN2 (0.51) MAPTALDH1A1MAPK1TOP1RAB9A
SCHEMBL9944251 0.82 MAPT (0.55) MAPTALDH1A1MAPK1RAB9ANPC1
SCHEMBL9944197 0.82 TAS1R3 (0.52) MAPTALDH1A1MAPK1TOP1KCNQ3
SCHEMBL9944212 0.80 TAS1R3 (0.60) MAPTALDH1A1MAPK1TOP1RAB9A
SCHEMBL5973851 0.78 NPC1 (0.65) MAPTMAPK1TOP1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG MAPT 150/4885ALDH1A1 128/4885MAPK1 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.